1PCN-101 (R-ketamine) for Treatment Resistance Depression

Time: 10:25 am
day: Day One

Details:

• PCN-101 is being developed by Perception Neuroscience for TRD and other mood disorders
• A Phase 1 SAD study in HV was completed which demonstrated good tolerability and safety
• Thoughts on the potential for a wider therapeutic window will be discussed.

Speakers: